NVCR · NovoCure Ltd
$15.30
+0.10 (+0.63%)
At close · Jul 30
Market Cap
$1.77B
Shares
116.45M
NovoCure Ltd Earnings Call Transcripts
Every quarterly earnings call for NovoCure Ltd (NVCR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼2%
$131.00M
−$26.58M
'22 Q3
22-10-27
▼3.6%
$128.43M
−$37.30M
'22 Q4
23-02-23
▼11.2%
$122.18M
−$53.06M
'23 Q1
23-05-04
▼10.5%
$126.05M
−$57.42M
'23 Q2
23-07-27
▼2.8%
$127.32M
−$49.48M
'23 Q3
23-10-26
▲4.2%
$133.78M
−$47.04M
'23 Q4
24-02-22
▲13.4%
$138.50M
−$38.76M
'24 Q1
24-05-02
▲19.3%
$150.36M
−$33.38M
'24 Q2
24-07-25
▲21.8%
$155.09M
−$30.57M
'24 Q3
24-10-30
▲20.5%
$161.27M
−$66.30M
'24 Q4
25-02-27
▲11.9%
$154.99M
−$34.32M
'25 Q1
25-04-24
▲5.6%
$158.81M
−$40.14M
'25 Q2
25-07-24
▲7.8%
$167.20M
−$37.27M
'25 Q3
25-10-30
▲8.1%
$174.35M
−$24.50M
'25 Q4
26-02-26
▲12.3%
$174.06M
−$71.14M
'26 Q1
26-04-30
LATEST
▲15.6%
$183.58M
−$15.66M
'26 Q2
26-07-23
Earnings call
FY26 · Q2
2026-07-23
Q2 2026 Earnings Conference Call
Revenue
$183.58M
▲ 15.6% YoY Diluted EPS
$-0.13
Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
NovoCure Ltd Q1 FY2026 Earnings Call
Confident tone
Optune Pax pancreatic launch
GBM / Optune Gio core business
Panova-4 metastatic pancreatic data
Revenue
$174.06M
▲ 12.3% YoY Diluted EPS
$-0.62
Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
NovoCure Ltd Q4 FY2025 Earnings Call
Positive tone
GBM core business and active patient growth
Geographic expansion and new market launches
Regulatory milestones and submissions
Revenue
$174.35M*
▲ 8.1% YoY Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
NovoCure Ltd Q3 FY2025 Earnings Call
Positive tone
Lung cancer launch challenges
GBM business growth
Japan launch for lung cancer
Revenue
$167.20M
▲ 7.8% YoY Diluted EPS
$-0.33
Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-24
NovoCure Ltd Q2 FY2025 Earnings Call
Confident tone
Optune Lua launch in non-small cell lung cancer
PANOVA-3 pancreatic cancer data and PMA filing
METIS brain metastases trial and FDA submission
Revenue
$158.81M
▲ 5.6% YoY Diluted EPS
$-0.36
Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
NovoCure Ltd Q1 FY2025 Earnings Call
Confident tone
OptuneLua NSCLC US launch
Panova-3 pancreatic cancer data at ASCO
Reimbursement and revenue ramp
Revenue
$154.99M
▲ 11.9% YoY Diluted EPS
$-0.31
Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
NovoCure Ltd Q4 FY2024 Earnings Call
Confident tone
GBM core business growth
Optune Lua non-small cell lung cancer launch
Gross margin and operating expense outlook
Revenue
$161.27M*
▲ 20.5% YoY Gross margin
79.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
NovoCure Ltd Q3 FY2024 Earnings Call
Confident tone
Optune Lua NSCLC launch
Executive leadership transitions
Reimbursement and CMS for lung
Revenue
$155.09M
▲ 21.8% YoY Diluted EPS
$-0.28
Gross margin
77.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-25
NovoCure Ltd Q2 FY2024 Earnings Call
Confident tone
Non-small cell lung cancer (NSCLC) launch readiness
Glioblastoma (GBM) commercial growth
Clinical pipeline progress
Revenue
$150.36M
▲ 19.3% YoY Diluted EPS
$-0.31
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
NovoCure Ltd Q1 FY2024 Earnings Call
Positive tone
METIS Phase III trial in brain metastases
INNOVATE-3 ovarian cancer data
LUNAR / NSCLC regulatory pathway
Revenue
$138.50M
▲ 13.4% YoY Diluted EPS
$-0.36
Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
NovoCure Ltd Q4 FY2023 Earnings Call
Confident tone
Lung cancer launch (LUNAR)
Clinical pipeline readouts
GBM commercial growth
Revenue
$133.78M*
▲ 4.2% YoY Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
NovoCure Ltd Q3 FY2023 Earnings Call
Revenue
$127.32M
▼ 2.8% YoY Diluted EPS
$-0.46
Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
NovoCure Ltd Q2 FY2023 Earnings Call
Revenue
$126.05M
▼ 10.5% YoY Diluted EPS
$-0.54
Gross margin
73.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
NovoCure Ltd Q1 FY2023 Earnings Call
Revenue
$122.18M
▼ 11.2% YoY Diluted EPS
$-0.50
Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
NovoCure Ltd Q4 FY2022 Earnings Call
Revenue
$128.43M
▼ 3.6% YoY Diluted EPS
$-0.36
Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
NovoCure Ltd Q3 FY2022 Earnings Call
Revenue
$131.00M
▼ 2% YoY Diluted EPS
$-0.25
Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
NovoCure Ltd Q2 FY2022 Earnings Call
Revenue
$140.87M
▲ 5.5% YoY Diluted EPS
$-0.23
Gross margin
79.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
NovoCure Ltd Q1 FY2022 Earnings Call
Revenue
$137.55M
▲ 2.1% YoY Diluted EPS
$-0.04
Gross margin
79.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
NovoCure Ltd Q4 FY2021 Earnings Call
Revenue
$133.21M
▼ 7.5% YoY Diluted EPS
$-0.25
▼ 725% YoY Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
NovoCure Ltd Q3 FY2021 Earnings Call
Revenue
$133.61M
▲ 0.7% YoY Diluted EPS
$-0.13
▼ 244.4% YoY Gross margin
77.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
NovoCure Ltd Q2 FY2021 Earnings Call
Revenue
$133.52M
▲ 15.2% YoY Diluted EPS
$-0.14
▼ 800% YoY Gross margin
78.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
NovoCure Ltd Q1 FY2021 Earnings Call
Revenue
$134.69M
▲ 32.3% YoY Diluted EPS
$-0.04
▼ 200% YoY Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
NovoCure Ltd Q4 FY2020 Earnings Call
Revenue
$143.95M
▲ 45.1% YoY Diluted EPS
$0.04
Gross margin
80.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
NovoCure Ltd Q3 FY2020 Earnings Call
Revenue
$132.66M
▲ 44.1% YoY Diluted EPS
$0.09
▲ 350% YoY Gross margin
78.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
NovoCure Ltd Q2 FY2020 Earnings Call
Revenue
$115.92M
▲ 33.7% YoY Diluted EPS
$0.02
Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
NovoCure Ltd Q1 FY2020 Earnings Call
Revenue
$101.83M
▲ 38.9% YoY Diluted EPS
$0.04
Gross margin
75.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
NovoCure Ltd Q4 FY2019 Earnings Call
Revenue
$99.23M
▲ 42.4% YoY Gross margin
75.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1645113
CUSIP
G6674U108
13F (30d)
60 filings
37 filers
Visit website
Investor relations